Dr. Ray O’Connor discusses the latest clinical studies on therapeutics, including the use of anabolic steroids which have serious adverse effects such as cardiovascular and psychiatric morbidity. A case-control study found an increase in mortality among AAS users compared to a control group. A trial on beta-blocker treatment post myocardial infarction with preserved ejection fraction did not show a lower risk of death or new myocardial infarction with long-term beta-blocker use. A systematic review on the duration of dual antiplatelet therapy for older adults after PCI found no differences in adverse events for different durations, but shorter DAPT was associated with a lower risk of bleeding.
Source link
You might be interested in…Therapeutics Update
